[headline announcement Nuggets]
CGN New Energy (01811): 1642.6 gigawatt-hours of electricity generated in July, an increase of 3.6% over the same period last year.
$CGN New Energy (01811.HK) $According to the announcement, the company and its subsidiaries completed 1642.6 gigawatt-hours of electricity generation according to the consolidated statement in July 2022, an increase of 3.6 per cent over the same period last year.
In the seven months ended July 31, 2022, the group completed a total of about 112,000 gigawatt hours of electricity this year, an increase of 3.2% over the same period last year.
Comments:China General Nuclear Corporation is the largest nuclear power company in China and the third largest nuclear power company in the world. In recent years, CGN has made great efforts to develop non-nuclear clean energy, wind power, solar and other non-nuclear new energy projects have formed a global layout, projects are distributed in 17 countries around the world.
Since its listing in 2014, the company's new energy power generation business has developed rapidly. As of December 31, 2021, the company's total installed capacity reached 8.4GW, including wind power installed capacity 3.85GW, solar power installed capacity 1.14GW, a total of 4.99GW, accounting for 59.3%. It has been transformed from a company dominated by traditional energy power generation to a company dominated by new energy power generation at the beginning of listing.
In recent years, global energy is undergoing profound changes from high-carbon to low-carbon, from inefficient to efficient. According to the climate target of "30ram60" in China, the total installed capacity of wind power and solar power will reach more than 1200GW, while the total installed capacity of wind power and solar power in China will be 634GW by the end of 2021. According to this, it is conservatively estimated that the annual compound growth rate of wind power and solar power capacity in China will be 7.34% from 2022 to 2030.
The total installed capacity of new energy in the world exceeds that of 39.2GW, of which the installed capacity of domestic new energy is about 28GW, and that of overseas new energy is about 11.2GW. According to Guoxin Securities Hong Kong, the group's new operation capacity of new energy will remain above 3GW every year, and the installed scale of new energy in China will reach 40GW by the end of the 14th five-year Plan.
[key announcement Nuggets]
FIT HON TENG (06088) released interim results: profit attributable to shareholders was $85.117 million, up 818.79% from a year earlier.
FIT HON TENG reported that revenue for the six months ended June 30, 2022, was about $2.101 billion, up 6.02 per cent from a year earlier, while profits attributable to company owners were $85.117 million, up 818.79 per cent from a year earlier. Basic earnings per share are 1.23 cents.
Comments:The company's traditional business mainly includes mobile devices, communications infrastructure, computers and consumer electronics products. Revenue from traditional businesses (73% of revenue in 2021) fell 2% year-on-year in 2021, mainly due to losses caused by the elimination of wired headphones and optical module business solutions for brand companies' new smartphones. The impact of these two negative factors continues, and the company's traditional business may continue to decline in 2022.
At the same time, in 2021, the company is focused on implementing the "34th 3" strategy, and the high-margin product portfolio, including electric vehicle products, 5G AIoT products and acoustic products, has made satisfactory progress. The smart accessories sector continued to be the main driver of growth (revenue increased by 59.4%); revenue from the electric vehicle, industrial and medical sectors also increased by 21.9%, thanks to rapid income growth from core electric vehicle customers.
Looking ahead, the company aims to expand the customer base and market share of its smart accessories division (such as expanding micro-speakers to customers other than Apple Inc) and increase revenue from electric vehicle products from customers other than Tesla, Inc.. According to Huatai, the company's high-margin product portfolio will further boost gross profit margin in the next 2-3 years, and the proportion of high-margin product portfolio in total revenue is expected to reach more than 29% in 2023.
Between 2018 and 2021, the company's automotive, industrial and healthcare (AIM) businesses accounted for 4 per cent of total revenue, up from 2 per cent. At present, the company has reached a good cooperative relationship with major North American customers in charging cable control devices (CPD), connectors and wireless charger products. China International Capital Corporation predicts that the company's AIM business revenue will achieve 11% year-on-year growth in 2022, which is expected to become one of the main drivers of the company's overall revenue growth.
BeiGene, Ltd. (06160): positive results have been achieved in the global phase 3 trial of Raylizumab in the treatment of first-line unresectable hepatocellular carcinoma
BeiGene, Ltd. issued an announcement that tirailizumab (Chinese trade name: Baize an ®) phase 3 global clinical trial RATIONALE 301 study reached the main end point, in the treatment of first-line unresectable hepatocellular carcinoma (HCC) adult patients, tirelizumab showed non-inferiority in overall survival (OS) compared with sorafenib, its safety characteristics were consistent with previous studies, and no new safety warnings were reported. The study included more than 600 patients from the United States, Europe and Asia.
Comments:BeiGene, Ltd. Co., Ltd. is a commercial biotechnology company specializing in research, development, production and commercialization of innovative drugs. The business covers all over the world. Three products have been approved for sale, including BGB-3111, BGB-A317 and BGB-290. There are also eight products in the clinical stage.
In the second quarter of 2022, sales of independent research and development products Baiyueze ®, Baize an ®, and Amgen Inc authorized products increased. Of this total, Baiyueze ®had global sales of US $128.7 million, an increase of 203 per cent over the same period last year. Sales of Baze an ®in China were $104.9 million, up 40 per cent from the same period last year.
As more indications are included in the National Medicare Drug catalogue (NRDL) and the expansion of Medicare reimbursement has led to an increase in demand from new patients, Bazeam ®has achieved sustained growth in market penetration and market share among the nine approved indications. The company's R & D expenditure in the second quarter was US $378.2 million, an increase of 6.2% over the same period last year.
[list of important announcements for Hong Kong stocks]